Follow-On Biologics' Other Pathway: Mechanisms To Resolve Patent Disputes Vary In Legislation
Executive Summary
The debate over follow-on biologics legislation has largely focused on the length of data exclusivity that should be awarded to innovators. But provisions for resolving patent disputes between innovators and follow-on applicants are also a source of contention
You may also be interested in...
Sandoz Will Steer Clear Of U.S. Biosimilars Pathway, Use Other Applications
Drug companies looking to bring biosimilars to the U.S. market will use existing regulatory pathways like 505(b)(2) or an outright Biologics Licensing Application over a new regulatory pathway provided in the health care reform legislation because of provisions in the new pathway that favor brands, Jeff George, the head of Sandoz, predicted
Sandoz Will Steer Clear Of U.S. Biosimilars Pathway, Use Other Applications
Drug companies looking to bring biosimilars to the U.S. market will use existing regulatory pathways like 505(b)(2) or an outright Biologics Licensing Application over a new regulatory pathway provided in the health care reform legislation because of provisions in the new pathway that favor brands, Jeff George, the head of Sandoz, predicted
U.S. Biosimilars: The "Devil's In The Details," Sandoz Chief Says
Regulatory pathways like 505(b)(2) and BLA, not the new one created through health care legislation, may be best for biosimilars, Sandoz CEO George says.